<DOC>
	<DOCNO>NCT00202865</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center , placebo-controlled study two parallel treatment group ( placebo infliximab ) subject ankylose spondylitis ( AS ) evaluate efficacy infliximab 3 mg/kg .</brief_summary>
	<brief_title>Evaluation Low Dose Infliximab Ankylosing Spondylitis ( Study P04352 )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Are men woman &gt; =18 year age Screening . Female subject childbearing potential ( include woman less 1 year postmenopausal woman become sexually active study ) must use acceptable method birth control ( eg , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( eg , hysterectomy tubal ligation ) , must continue precaution 6 month receive last study agent infusion , negative serum pregnancy test prior enrollment . Additionally , male subject sexually active , woman childbearing potential , ensure partner use adequate contraception Have diagnosis AS accord modified 1984 New York criterion , prior Screening . Have active disease , evidence BASDAI score &gt; =4 Baseline Screening Screening test must meet following criterion : Hemoglobin : &gt; =9.0 g/dL ( 5.6 mmol/L ) men &gt; =8.5 g/dL ( 5.3 mmol/L ) woman Serum transaminase level must within 3 time ULN Serum creatinine &lt; =1.4 mg/dL ( 107umol/L ) . Are capable read understand subject assessment form provide write informed consent . Have document negative reaction PPD skin test ( PPD induration &lt; 5 mm ) perform within 1 month prior first study infusion . If PPD negative , chest xray still require . Subjects must understand English French . Have serious infection ( eg , sepsis , hepatitis , abscess , pneumonia , pyelonephritis ) , hospitalize infection , treat intravenous ( IV ) antibiotic infection within 8 week prior randomization . Less serious infection ( eg , acute upper respiratory tract infection , simple urinary tract infection ) need consider exclusion discretion investigator . Have ever chronic recurrent infectious disease include , limited , chronic renal infection , chronic chest infection ( eg , bronchiectasis ) , sinusitis , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremitting cystitis ) , open , drain , infected skin wound , ulcer . Have ever opportunistic infection ( eg , herpes zoster ( shingle ) , cytomegalovirus , pneumocystis carinii , aspergillosis , histoplasmosis ) Have document atypical mycobacteria infection . Have active TB recent close contact individual active TB ever evidence latent TB . Have chest radiograph ( PA lateral ) display granulomas apical fibronodular disease suggestive previous TB determine investigator . Have document Hepatitis B ( surface antigen positive ) . Have document HIV . Have know malignancy history malignancy within 5year period prior Screening ( exception squamous basal cell carcinoma skin completely excise without evidence recurrence ) . Have history lymphoproliferative disease include lymphoma , multiple sclerosis , central demyelinate disorder , congestive heart failure . Have serious concomitant illness , one mention , might interfere participation trial . Have know allergy murine protein chimeric protein . Have ever receive previous treatment infliximab , etanercept antiTNF agent prior first study infusion . Are pregnant , nursing , plan pregnancy ( men woman ) trial within 6month period thereafter . Have contraindication study protocol component . Subjects contraindication MRI component study enrol , however , exempt MRI examination . Subjects unstable dos NSAIDS , DMARDs , analgesic corticosteroid Screening continue receive medication study . Subjects receive &gt; 10 mg prednisone ( equivalent ) daily . Have document history fibromyalgia confirm appropriate physician specialist ( ie , rheumatologist ) . Have document history total ankylosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>